J7677 – Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ7677
- Long description
- Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
- Short description
- Revefenacin inh non-com 1mcg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
D1GDrugs Administered through DME- Added
- July 1, 2019
- Last change
- July 1, 2019 – No change
Frequently asked questions
What is HCPCS code J7677?
J7677 is a HCPCS Level II code for revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram.
Does Medicare cover J7677?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J7660 – Isoproterenol hcl, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
- J7665 – Mannitol, administered through an inhaler, 5 mg
- J7667 – Metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 milligrams
- J7668 – Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 10 milligrams
- J7669 – Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligrams
- J7670 – Metaproterenol sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligrams
- J7674 – Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg
- J7676 – Pentamidine isethionate, inhalation solution, compounded product, administered through dme, unit dose form, per 300 mg
- J7680 – Terbutaline sulfate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
- J7681 – Terbutaline sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
- J7682 – Tobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligrams
- J7683 – Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
- J7684 – Triamcinolone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
- J7685 – Tobramycin, inhalation solution, compounded product, administered through dme, unit dose form, per 300 milligrams
- J7686 – Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg
- J7699 – Noc drugs, inhalation solution administered through dme
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.